Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

Neuroprotective Effect of a Novel Herbmedicine, Hepad on SH-SY5Y Cells

  • Kim, Eun Hye (Department of Biomedical Laboratory Science, School of Medicine, Eulji University) ;
  • Park, Byung-Jun (Young Jin Korea Medical Clinic) ;
  • Kim, Jung Seok (Department of Biomedical Laboratory Science, School of Medicine, Eulji University) ;
  • Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Choi, Hak Joo (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Kim, In Sik (Department of Biomedical Laboratory Science, School of Medicine, Eulji University)
  • Received : 2013.03.22
  • Accepted : 2013.03.25
  • Published : 2013.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Parkinson's disease is a neurodegenerative disease with a wide range of dopaminergic neuron cell death in the substantia nigra. Oxidative stress and neural degeneration are suggested to be involved in the pathogenesis of Parkinson's disease. In this study, we investigated whether a novel herbmedicine, Hepad protects against 1-methyl-4-phenylpyridnium [MPP(+)]-induced dopaminergic neurotoxicity in SH-SY5Y cells. We found that pretreatment with Hepad significantly increases the proliferation of SH-SY5Y cells (P<0.05) and reversed the loss of cell viability induced by $MPP^+$. Hepad may be a promising neuroprotective agent for the treatment of neurodegenerative disorders such as Parkinson's disease.

Keywords

Acknowledgement

Supported by : Daejeon University

References

  1. Blandini F, Armentero MT. Animal models of parkinson's disease. FEBS J. 2012. 279: 1156-1166. https://doi.org/10.1111/j.1742-4658.2012.08491.x
  2. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in parkinson's disease. Prog Neurobiol. 2001. 65: 135-172. https://doi.org/10.1016/S0301-0082(01)00003-X
  3. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR. Deep brain stimulation for parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011. 68: 165.
  4. Dauer W, Przedborski S. Parkinson' disease: mechanisms and models. Neuron 2003. 39: 889-909. https://doi.org/10.1016/S0896-6273(03)00568-3
  5. de Lau LM, Breteler MM. Epidemiology of parkinson's disease. Lancet Neurol. 2006. 5: 525-535. https://doi.org/10.1016/S1474-4422(06)70471-9
  6. Jain S, Wood NW, Healy DG. Molecular genetic pathways in parkinson's disease: a review. Clin Sci (Lond). 2005. 109: 355-364. https://doi.org/10.1042/CS20050106
  7. Kidd PM. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000. 5: 502-529.
  8. Park BJ, Kim DH. A study on a case of treatment termination of parkinson's disease treated by 5 upright life cure regulations therapy. Institute of Oriental medicine of Dajeon University J. 2011. 19: 57-64.
  9. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of parkinson's disease. Mov Disord. 2001. 16: 507-510. https://doi.org/10.1002/mds.1099
  10. Zhang ZG, Wu L, Wang JL, Yang JD, Zhang J, Zhang J, Li LH, Xia Y, Yao LB, Qin HZ, Gao GD. Astragaloside IV prevents $MPP^+$-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem. 2012. 364: 209-216. https://doi.org/10.1007/s11010-011-1219-1